Award

Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes

Description: Compulsivity is characterized by a repetitive, irresistible urge to perform a behavior, the experience of loss of voluntary control over this intense urge, the diminished ability to delay or inhibit thoughts or behaviors, and the tendency to perform repetitive acts in a habitual or stereotyped manner. Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders that emerge in childhood (autism spectrum disorder, ASD; obsessive-compulsive disorder, OCD) or adolescence (substance abuse). Our approach integrates clinical data sets for ‘addictive’ (ADHD high risk for substance use), ‘anxious’ (OCD) and ‘stereotypical’ (ASD) compulsive behaviors with highly predictive animal models for new pharmacotherapy. In a series of ‘proof-of-concept’ studies, the cohesion of structural neuroimaging studies (MRI/DTI), neurochemistry (MRS/microdialysis), behavior, genetics (GWAS), proteomics and (Bayesian) machine learning tools in both male and female paediatric clinical populations and behavioral animal models will seek to better understand underlying mechanisms related to glutamate dysfunction in frontostriatal circuits and its remediation / prevention by early intervention studies with glutamate-based (riluzole and memantine) clinically used drugs. The leading drug-based interventions will be tested in pilot Phase IIb-like studies for ‘proof-of-principle’ efficacy in paediatric OCD and ASD populations. This approach will 1) establish predictive neural, genetic and molecular markers of compulsivity in pediatric populations; 2) provide evidence of disorder modifying pharmacologic strategies as a therapeutic approach; 3) develop a novel animal model for pharmaceutical screening and proof of concept studies, 4) build and valorize a translational biomarker compulsivity database and 5) provide pilot efficacy and safety data in paediatric clinical populations to support future large scale clinical trials according to these strategies.
Amount: €6,000,000
Funding type: research
Funder scheme: FP7 - CP-FP
Start date: 2012-01-01
End date: 2018-06-30
Institution: STICHTING RADBOUD UNIVERSITEIT
Funded outputs count: 120
Funder award ID: 278948
OpenAlex ID: G420975083
2026 · Viola Hollestein, Tom Claassen, et al. · Translational Psychiatry
2026 · Cardoso Saraiva, L., Sato, J., et al. · ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)
2025 · Viola Hollestein · Radboud University Press eBooks
2025 · Zimmer, Luc, Manahan-Vaughan, Denise, et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill)
2025 · Dorothea L. Floris, Alberto Llera, et al. · Nature Mental Health · 22
2023 · Mairéad Sullivan, Fernando Fernandez-Aranda, et al. · Neuroscience & Biobehavioral Reviews · 13
2023 · Joanes Grandjean, Gabriel Desrosiers-Gregoire, et al. · Nature Neuroscience · 119
2023 · Ruiyang Ge, Yuetong Yu, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 20
2022 · Ting Mei, Natalie J. Forde, et al. · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · 15
2022 · Iliyan Ivanov, Premika S.W. Boedhoe, et al. · Journal of Affective Disorders · 22
2022 · Rachel M. Brouwer, Marieke Klein, et al. · Nature Neuroscience · 227
2022 · Amirhossein Modabbernia, Didac Vidal-Pineiro, et al. · bioRxiv (Cold Spring Harbor Laboratory)
2022 · Jilly Naaijen, Martina Arenella, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
2021 · Josi M. A. Driessen, Inti A. Brazil, et al. · Personality Disorders Theory Research and Treatment · 9
Year
Topic